Joseph Knight has been appointed president of InnAVasc.
“We are pleased to announce Joe’s appointment as resident,” says Jeffrey Lawson, chief executive officer of InnAVasc. “As we continue the development of the Bullet Proof vascular graft, we wanted someone with a breadth of knowledge in bringing forward medical technologies. We believe that Joe’s experience and track record will be invaluable to our successful development and commercialisation of Bullet Proof.”
Knight joins InnAVasc with nearly 15 years of experience in medical device innovation. He has been part of the intellectual property development, business, and strategic planning for four different ventures – including iRhythm Technologies, and as founder/chief executive officer of Medici Medical Technologies.
Most recently, Knight spent 5 years at Medtronic in various roles in marketing, business development, and strategy. In his last role with Medtronic, as director of Strategic Marketing, he developed and executed the strategy that led to Medtronic’s ~$100M acquisition of CardioInsight. Knight also served 8 years as an infantry soldier in the US Army. He holds a PhD degree in Biomedical Engineering from the Swiss Federal Institute of Technology, an MBA from the Fuqua School of Business at Duke University, and an MS/BS in Biomedical Engineering from the University of South Florida. He also completed Stanford’s Biodesign Fellowship.
“There are numerous unmet clinical needs related to haemodialysis vascular grafts,” says Knight. “Results to date of InnAVasc’s Bullet Proof technology show significant promise to alleviate many of these needs…I look forward to joining the InnAVasc team.”
